Glutamate neurotransmission system may be involved with depression risk

Researchers using a new approach to identifying genes associated with depression have found that variants in a group of genes involved in transmission of signals by the neurotransmitter glutamate appear to increase the risk of depression. The report published in the journal Translational Psychiatry suggests that drugs targeting the glutamate system may help improve the limited success of treatment with current antidepressant drugs.

"Instead of looking at DNA variations one at a time, we looked at grouping of genes in the same biological pathways and found that a set of genes involved in glutamatergic transmisson was associated with the risk of depression," says Jordan Smoller, MD, ScD, director of the Psychiatric and Neurodevelopmental Genetics Unit in the Massachusetts General Hospital (MGH) Department of Psychiatry, senior author of the study. "Our findings are particularly interesting in light of recent studies showing that drugs affecting glutamate transmission can have rapid antidepressant effects."

While the risk of depression clearly runs in families, the genome-wide association studies typically used to identify gene variants that increase disease risk have been unable to find strongly associated genes. The research team – which includes investigators from the Broad Institute of MIT and Harvard and other research centers in the U.S., Australia and the Netherlands – adopted a strategy called gene set pathway analysis.

Starting with a set of genes that previous studies had implicated in depression, they used an analysis process called to scan the for information on the of these genes. Based on those findings, they identified 178 biological pathways that included these genes. Only one of those pathways – the one involved in transmission of carried by glutamate – was significantly associated with the risk for depression.

"Glutamate is the excitatory transmitter most widely used by the central nervous system, and several studies in animals and humans have suggested that it may play a role in depression," explains Smoller, an associate professor of Psychiatry at Harvard Medical School. "Most intriguingly, recent studies have found that ketamine – a drug known to block one glutamate receptor – appears to have antidepressant effects that are much faster than those of traditional antidepressants, which can take several weeks to become effective. Now additional research needs to confirm these findings and investigate exactly how variation in glutamate function affects brain systems involved in depression."

Related Stories

Researchers explore the antidepressant effects of ketamine

Feb 21, 2008

Drug treatments for depression can take many weeks for the beneficial effects to emerge. The excruciating and disabling nature of depression highlights the urgency of developing treatments that act more rapidly. Ketamine, ...

'Special K' could relieve depression

Jun 07, 2012

(Medical Xpress) -- Recreational drug and anaesthetic, ketamine, is being trialled in people with severe depression and is providing almost instant relief from symptoms, offering fresh hope of a quick new ...

Faster-acting antidepressants closer to becoming a reality

Jul 24, 2007

A new study has revealed more about how the medication ketamine, when used experimentally for depression, relieves symptoms of the disorder in hours instead of the weeks or months it takes for current antidepressants to work. ...

Recommended for you

When it hurts to think we were made for each other

48 minutes ago

Aristotle said, "Love is composed of a single soul inhabiting two bodies." Poetic as it is, thinking that you and your partner were made in heaven for each other can hurt your relationship, says a new study.

What is whisper therapy?

6 hours ago

Consider the stress of modern life, with its cacophonous soundtrack of traffic, electronics and construction. It's no wonder so much of our leisure time is spent in a quest to let go of the workday and unwind. ...

User comments